SCHEMBL4701411

SCHEMBL4701411

COc1ccc2[nH]c3c(c2c1)CCn1cncc1-3

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.56
CYP1A2 P05177 6/20 0.56
KMT2A Q03164 4/20 0.56
HTR7 P34969 4/20 0.56
CYP2D6 P10635 4/20 0.56
TDP1 Q9NUW8 3/20 0.56
ALOX15 P16050 3/20 0.56
RECQL P46063 3/20 0.56
MEN1 O00255 3/20 0.56
CYP3A4 P08684 2/20 0.56
HTR2A P28223 2/20 0.56
HTR2C P28335 2/20 0.56
CASP1 P29466 2/20 0.56
HTR6 P50406 2/20 0.56
MAPK10 P53779 1/20 0.53
RIPK1 Q13546 1/20 0.53
MAPT P10636 5/20 0.51
ALDH1A1 P00352 4/20 0.51
HPGD P15428 3/20 0.51
POLB P06746 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14345706 0.83 CYP1A2 (0.53) KDM4ECYP1A2KMT2AHTR7CYP2D6
SCHEMBL2457583 0.79 KDM4E (0.47) KDM4ECYP1A2KMT2AHTR7MEN1
SCHEMBL4704080 0.78 CYP1A2 (0.58) KDM4ECYP1A2KMT2AHTR7CYP2D6
SCHEMBL4699371 0.75 CYP1A2 (0.53) KDM4ECYP1A2KMT2AHTR7CYP2D6
SCHEMBL14345741 0.74 CYP1A2 (0.57) KDM4ECYP1A2KMT2AHTR7CYP2D6
SCHEMBL4699401 0.73 CYP1A2 (0.51) KDM4ECYP1A2KMT2AHTR7CYP2D6
SCHEMBL4699582 0.73 CYP1A2 (0.61) KDM4ECYP1A2KMT2AHTR7CYP2D6
SCHEMBL8025906 0.73 CYP1A2 (0.61) KDM4ECYP1A2KMT2AHTR7CYP2D6
SCHEMBL8037852 0.73 CYP1A2 (0.58) KDM4ECYP1A2KMT2AHTR7CYP2D6
SCHEMBL14345924 0.73 CYP1A2 (0.63) KDM4ECYP1A2KMT2AHTR7CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1390367-B1 DIHYDROIMIDAZO 5,1-A -$G(b)-CARBOLINE DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINE MACEF (FR) 2008-07-09 EP claimed
US-7291627-B2 Dihydroimidazo[5.1-a]-beta-carboline derivatives, method for their preparation, and their application as a drug MACEF (FR) 2007-11-06 US claimed
US-20060089372-A1 Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine MACEF (FR) 2006-04-27 US claimed
EP-1390367-B1 DIHYDROIMIDAZO 5,1-A -$G(b)-CARBOLINE DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINE MACEF (FR) 2008-07-09 EP disclosed
US-7291627-B2 Dihydroimidazo[5.1-a]-beta-carboline derivatives, method for their preparation, and their application as a drug MACEF (FR) 2007-11-06 US disclosed
US-20060089372-A1 Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine MACEF (FR) 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089372-A1 Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine GDI2, GDI1, CYP2A7 KDM4E 2939/4885CYP1A2 37/4885KMT2A 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.